Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
BMS walks away from $80M neurodegeneration bet after phase 1
The Prothena-partnered program, dubbed BMS-986495, was being developed as a potential treatment for neurodegenerative diseases.
Marissa Russo
Oct 29, 2026 10:53am
BMS joins 3-year collab to boost cancer trial participation
Oct 27, 2026 5:00am
BMS sheds light on patient death in CAR-T trial
Oct 26, 2026 7:00am
ESMO: BMS’ Massacesi hails PD-L1xVEGF data as ‘very promising’
Oct 25, 2026 7:03pm
BMS leads Pathos' $237M series E alongside Alzheimer's link-up
Oct 23, 2026 8:00am
BMS doubles up with pivotal wins in lung disease, solid tumor
Oct 12, 2026 8:05am
